期刊文献+

抗生素联合日达仙治疗重症肺炎患者的临床疗效观察 被引量:1

Analysis of Clinical Efficacy of Antibiotics and Zadaxin on Treatment of Patients with Severe Pneumonia
暂未订购
导出
摘要 目的:评价抗生素联合日达仙治疗重症肺炎患者的疗效和安全性。方法:收集本院120例重症肺炎患者的临床治疗资料,其中68例单独应用头孢哌酮/舒巴坦钠进行治疗,52例应用头孢哌酮/舒巴坦钠联合日达仙治疗。结果:单独应用头孢哌酮/舒巴坦钠与联合应用日达仙治疗重症肺炎的临床有效率分别是85.29%和96.15%,二者相比具有显著性差异(P<0.05);细菌清除率分别为69%和86%,二者相比具有显著性差异(P<0.05);联合应用日达仙治疗能够明显提高铜绿假单胞杆菌的清除率;不良反应发生率为7.0%和5.0%,二者相比没有明显差异(P>0.05)。结论:联合日达仙治疗重症肺炎患者的临床疗效明显优于单纯应用抗生素治疗,是治疗重症肺炎的有效方案。 Objective: To evaluate the efficacy and safety of antibiotic and Zadaxin on the treatment of patients with severe pneumonia. Method: Clinical treatment datas of 120 cases of patients with severe pneu- monia have been collected from our hospital . 68 cases were treated alone of cefoperazone / sulbactam , 52 were treated with cefoperazone / sulbactam and zadaxin. Result: Clinical efficiency of alone cefoperazone / sulbactam and cefoperazone / sulbactam combination of zadaxin for treatment of severe pneumonia was re- spectively 85.29% and 96.15% , there're the significant difference between two groups (P 〈0.05 ), and bac- terial clearance rate was respectively 69% and 86%, there're significant difference between two groups ( P 〈0.05 ) ; application of cefoperazone / sulbactam combination of Zadaxin can significantly improve the clear- ance of pseudomonas aeruginosa a cell of Bacillus ; adverse reactions of two groups was respectively 7.0% and 5.0% , There's no significant difference ( P〉 0.05 }. Conclusion: The clinical efficacy of antibiotic and Zadaxin treatment for patients with severe pneumonia is significantly better than the simple application of an- tibiotic , this an effective programme for the treatment of severe pneumonia.
出处 《河北医学》 CAS 2013年第4期513-516,共4页 Hebei Medicine
关键词 日达仙 重症肺炎 联合应用 Zadaxin Severe pneumonia Combination application
  • 相关文献

参考文献2

二级参考文献5

  • 1曹卉,柳青,明建扩.免疫调节剂对荷瘤小鼠红细胞免疫粘附功能及抑瘤生长的研究[J].济宁医学院学报,1996,19(1):24-26. 被引量:2
  • 2Eckert K,Grunberg E,Immenschuh P,et al. Interleukin-2-actirated killer cell level in colorectal tumor patients:evaluation of in vitro effects by prothymosin alphal [J]. J Cancer Res Clin Oncol, 1997,123(8): 420—428.
  • 3Baxevanis C N,Gritzapis A D, Spanakos G,et al. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha [J]. Cancer Immunol Immunother, 1995,40 (6):410—418.
  • 4Pica F,Frauaschetti M,Matteucci C,et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma [J]. Anticancer Res, 1998,18(5A):3571—3578.
  • 5Stefanini G F,Fosehi F G,Castelli E,et al. Alpha-1-thymosin and transcatheter arterial ehemoembolization in hepatocellular carcinoma patients: a preliminary experience [J]. Hepatogastroenterology. 1998,45(19):209—215.

共引文献59

同被引文献7

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部